All In Biotech

Drug Trial Radar · NCT06833008

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

42

Actual

Start

Mar 14, 2025

Primary completion

Apr 4, 2028

Study completion Apr 4, 2028

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Feb 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body.

Conditions

  • Advanced Solid Tumor

Interventions

  • IPN01195Drug

    IPN01195 will be administered at assigned dose level.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Percentage of participants with dose limiting toxicity (DLT)Time frame: Part A: within 28 days of first dose.
  2. Part A and B: Percentage of participants experiencing treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TE SAEs).Time frame: From the first IPN01195 administration to 30 days after last dose.
  3. Part A and B: Percentage of participants with dose interruptions and permanent treatment discontinuationsTime frame: From the first study drug administration to 30 days after last dose.
  4. Part B: Objective response rate (ORR)Time frame: Part B: At end of study (up to approximately 3 years)

Locations

13 sites in 4 countries. Site status is shown where the registry gives one.

  • START Mid-West

    Grand Rapids, Michigan

  • Sarah Cannon Research Institute (SCRI) - Nashville

    Nashville, Tennessee

  • Mary Crowley Cancer Research Centers - Medical City Hospital - Dallas

    Dallas, Texas

  • START Mountan Region

    West Valley City, Utah

  • Virginia Cancer Specialist- Fairfax

    Fairfax, Virginia

  • Centre Léon Bérard - Lyon

    Lyon, France

  • Paris Saint-Louis

    Paris, France

  • IGR-Villejuif

    Villejuif, France

  • Istituto Nazionale dei Tumori

    Milan, Italy

  • Istituto Nazionale Tumori IRCCS - Fondazione Pascale

    Naples, Italy

  • Val D'Hebron

    Barcelona, Spain

  • Hospital Universitario Quirónsalud Madrid

    Madrid, Spain

  • M.D. Anderson Center Madrid

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.